---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-168973"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:14:09.009860+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProKidney to purchase Greensboro, NC manufacturing facility for $25.5M; eligible for $13.3M tax credits

## Summary
- Purchase price of ~$25.5M cash for a 210K sq ft facility and 22 acres; expected close by end of June 2023.
- Company eligible for up to $13.3M in tax credits from city, county, and state; requires 330+ new jobs by Dec 2028 and ~$458M investment by Dec 2027.
- Facility will support commercial manufacturing for REACT cell therapy, currently in Phase 3 trials for diabetic CKD.
- Cash as of March 31, 2023 expected to fund operations through interim results from proact 1 trial, anticipated in late 2024.
- Company targeting BLA submission for FDA approval in 2026 with potential U.S. commercial launch later that year.

## SEC filing metadata
- accession: 0001193125-23-168973
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/0001193125-23-168973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/d475847d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-168973
- JSON: https://secwatch.observer/filing/0001193125-23-168973.json
- Plain text: https://secwatch.observer/filing/0001193125-23-168973.txt

## Key facts
- Material Agreements
  PROKIDNEY CORP. entered into the Agreement with the city of Greensboro, N.C., Guilford County, N.C., and the North Carolina State Economic Investment Committee valued at approximately $25.5 million (effective 2023-06-13).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: the city of Greensboro, N.C., Guilford County, N.C., and the North Carolina State Economic Investment Committee
  - Value: approximately $25.5 million
  - Effective: 2023-06-13
  source text: On June 13, 2023, ProKidney Corp. (the “Company”) announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company’s future commercial manufacturing needs for REACT ® , its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic chronic kidney disease.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000119312523168973/0001193125-23-168973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.